Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon

Mpoh, MauriceMbwe; Deli, Vandi; Daniel, TolloTollo; Salvo, Francesco

doi:10.4103/ijmy.ijmy_88_23

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only primary quantitative studies were selected from the search output. The title of the study, year of study, study setting, study design, MDR-TB confirmed number of cases, MDR-TB/HIV co-infection proportion, and the outcome explored were characteristics retrieved from the studies (Table 1) [9–13,14 ▪▪ ,15–21,22 ▪▪ ,23,24 ▪▪ ,25–29,30 ▪ ,31 ▪ ,32–36,37 ▪▪ ,38–48,49 ▪▪ ,50 ▪ ].…”

Section: Search Methodsmentioning

confidence: 99%

Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management

Nyasulu,

Doumbia,

Ngah

et al. 2024

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review This review addresses the escalating global challenge of multidrug-resistant tuberculosis (MDR-TB) in Sub-Saharan Africa, with a focus on its complex comorbidity with HIV/AIDS. Emphasizing the urgency of the issue, the review aims to shed light on the unique healthcare landscape shaped by the convergence of high prevalence rates and intersecting complexities with HIV/AIDS in the region. Recent findings A notable increase in MDR-TB cases across Sub-Saharan Africa is attributed to challenges in timely diagnoses, treatment initiation, and patient treatment defaulting. The literature underscores the critical need for proactive measures to address diagnostic and treatment gaps associated with MDR-TB, particularly concerning its comorbidity with HIV/AIDS. Summary To effectively manage MDR-TB and its co-morbidity with HIV/AIDS, proactive screening programs are imperative. The review highlights the necessity of active follow-up strategies to ensure treatment adherence and reduce default rates, offering evidence-based insights for improved disease management in the region.

show abstract

Section: Search Methodsmentioning

confidence: 99%

Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management

Nyasulu,

Doumbia,

Ngah

et al. 2024

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

Agreement between Phenotypically Detected Linezolid Resistance and Mutations in rrl and rplC Genes of Mycobacterium tuberculosis Isolates Using Nanopore Sequencing

Sengupta,

Jain,

Ratnam

et al. 2024

The International Journal of Mycobacteriology

View full text Add to dashboard Cite

Background: Phenotypic drug susceptibility testing (DST) is considered the gold standard for detecting linezolid (LZD) resistance in Mycobacterium tuberculosis (MTB), but it is time-consuming. Nanopore sequencing offers a potentially faster alternative approach. This study evaluated the agreement between phenotypically detected LZD resistance and mutations in the rrl and rplC genes of MTB isolates using nanopore sequencing. Methods: Consecutive drug-resistant MTB isolates from pulmonary samples collected in 2021 underwent liquid culture (LC) DST for LZD. All resistant isolates and an equal number of susceptible isolates were subjected to targeted sequencing of the rrl and rplC genes using nanopore technology. Results: Sequencing identified a C154R mutation in the rplC gene in only one LZD-resistant isolate. No mutations were detected in the rrl gene. The agreement between sequencing and LC-DST for detecting LZD resistance was poor (Cohen’s kappa: 0.03571, 95% confidence interval [CI]: −0.034–0.105). Additionally, no significant association was found between LZD resistance and clinical or microbiological outcomes at 6-month follow-up. Conclusion: This study revealed a considerable discrepancy between phenotypic and genotypic detection of LZD resistance in MTB. Further research is needed to better understand the genetic mechanisms underlying LZD resistance and to develop reliable molecular diagnostics for rapid resistance detection.

show abstract

Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon

Cited by 2 publications

References 17 publications

Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management

Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management

Agreement between Phenotypically Detected Linezolid Resistance and Mutations in rrl and rplC Genes of Mycobacterium tuberculosis Isolates Using Nanopore Sequencing

Contact Info

Product

Resources

About